REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31)
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) of $232.62 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-07.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue · last filed 2013-05-07
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $232.62K, a 9.13% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $174.56K.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $254.26K, a 42.01% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $246.18K.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2012 was $931.00K.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2011 was $993.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | $232.62K 10-Q · filed 2013-05-07 | $407.17K derived: sum of 2 quarters · filed 2013-05-07 | $661.44K derived: sum of 3 quarters · filed 2013-05-07 | $907.62K derived: sum of 4 quarters · filed 2013-05-07 |
| 2012-12-31 | $174.56K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $428.82K derived: sum of 2 quarters · filed 2013-03-15 | $675.00K derived: sum of 3 quarters · filed 2013-03-15 | $931.00K 10-K · filed 2013-03-15 |
| 2012-09-30 | $254.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $500.44K derived: sum of 2 quarters · filed 2012-11-08 | $756.44K 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $246.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $502.18K 10-Q · filed 2012-08-09 | ||
| 2012-03-31 | $256.00K 10-Q · filed 2013-05-07 | |||
| 2011-12-31 | $804.00K 10-K · filed 2013-03-15 | |||
| 2011-09-30 | $438.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $953.33K 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | $514.87K 10-Q · filed 2012-08-09 | |||
| 2011-03-31 | $176.00K derived: 10-K 12 month − 10-K 9 month · filed 2013-03-15 | $993.00K 10-K · filed 2013-03-15 | ||
| 2010-12-31 | $817.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |